Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
19,139,684
-
Total 13F shares
-
6,818,719
-
Share change
-
+6,818,366
-
Total reported value
-
$60,295,418
-
Put/Call ratio
-
71%
-
Price per share
-
$8.84
-
Number of holders
-
62
-
Value change
-
+$60,292,285
-
Number of buys
-
61
Institutional Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) as of Q2 2025
As of 30 Jun 2025,
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,818,719 shares.
The largest 10 holders included
ARCH Venture Management, LLC, Foresite Capital Management IV, LLC, Almitas Capital LLC, venBio Partners LLC, VANGUARD GROUP INC, Foresite Capital Management V, LLC, PRICE T ROWE ASSOCIATES INC /MD/, Alphabet Inc., CITADEL ADVISORS LLC, and HSG Holding Ltd.
This page lists
62
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.